Affiliation:
1. Astrakhan State Medical University
121, Bakinskaya Str., Astrakhan, Russia, 414000
2. 1. Astrakhan State Medical University
121, Bakinskaya Str., Astrakhan, Russia, 414000
2. Territorial body of Federal State Surveillance Service in Healthcare for Astrakhan Region
27, Kommunisticheskaya Str., Astrakhan, Russia 414040
Abstract
The aim of the study was to estimate the economic damage by COPD, including direct medical and non-medical costs and indirect costs associated with premature deaths of working-age individuals.Materials and methods. First, estimation of the economic COPD burden in Astrakhan region (AR) was carried out using the clinical and economic analysis of the "cost of illness" (COI). Direct medical costs of inpatient, outpatient, ambulance and emergency medical care, as well as direct non-medical costs associated with the disability benefits payments, were taken into account. Indirect costs were defined as economic losses from undelivered products due to premature deaths of working-age individuals.Results. From 2015 to 2019, the economic COPD burden in AR amounted to 757.11 million rubles in total, which is equivalent to 0.03% of the gross regional product covering a five-year period of the study. Direct medical and non-medical costs totaled 178.02 million rubles. In the structure of direct medical expenses, expenses for inpatient, as well as ambulance and emergency medical care during the study period, increased by 92.5% and 45.5%, respectively. While the costs for the outpatient care decreased by 31.9%, the increase in direct non-medical costs associated with the disability benefits payments, increased by 5.1% (2019). Indirect losses amounted to 579.09 million rubles.Conclusion. The structure of the main damage is dominated by indirect losses in the economy associated with premature deaths of working-age individuals. In the structure of direct medical costs, inpatient care costs prevailed. These studies indicate the need to continue an advanced analysis of the economic burden of COPD, as well as to optimize the treatment and prevention of the exacerbations development of this disease.
Publisher
Volgograd State Medical University
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology,Pharmacy
Reference24 articles.
1. Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review. Int J Chron Obstruct Pulmon Dis. 2020;15:439-460. DOI: 10.2147/COPD.S234942.
2. Kuzmichev B.Yu., Voronina L.P., Tarasochkina D.S., Polunina O.S., Prokofieva T.V., Lipnitskaya E.A., Polunina E.A. Hyperhomocysteinemia as a risk factor for a complicated course of myocardial infarction against the background of the chronic obstructive pulmonary disease. Astrakhan medical journal. 2019; 14(3): 79-87. DOI: 10.17021/2019.14.3.79.87. Russian
3. Blanco I, Diego I, Bueno P, Fernández E, Casas-Maldonado F, Esquinas C, Soriano JB, Miravitlles M. Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique. International journal of chronic obstructive pulmonary disease. 2017;13:57–67. DOI: 10.2147/COPD.S150853
4. Chuchalin AG, Khaltaev N, Antonov NS, Galkin DV, Manakov LG, Antonini P, Murphy M, Solodovnikov AG, Bousquet J, Pereira MH, Demko IV. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. International journal of chronic obstructive pulmonary disease. 2014;9:963–974. DOI: 10.2147/COPD.S67283
5. WHO; World Health Organization. The top 10 causes of death. 2019. [Date of access 13 Jan 2021]. Available from: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献